✨ Free AI Report
Mochida Pharmaceutical Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Mochida Pharmaceutical Co., Ltd.
Company Research

Mochida Pharmaceutical Co., Ltd.: Business Overview, Financials & Competitive Analysis

Mochida Pharmaceutical manufactures and sells pharmaceuticals and healthcare products in Japan. The company primarily develops new drugs for treating intractable diseases and generic drugs, with therapeutic focus on c...

Analyst-debate audio for Mochida Pharmaceutical Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Mochida Pharmaceutical Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Japanese pharma with improving margins and strategic M&A positioning, but long-term growth consistency and valuation remain key...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Mochida Pharmaceutical Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Mochida Pharmaceutical Co., Ltd. Overview

Pro stress-test →

Mochida Pharmaceutical manufactures and sells pharmaceuticals and healthcare products in Japan. The company primarily develops new drugs for treating intractable diseases and generic drugs, with therapeutic focus on cardiology, obstetrics and gynecology, psychiatry, and gastroenterology. As a mid-cap Japanese pharmaceutical player, it has demonstrated improving profitability driven by operational efficiency gains.

Strategic Profile

Pro stress-test →

In fiscal year 2026, the company reported revenue of ¥117.0 billion (up 11% from FY 2025) with net income of ¥7.90 billion (up 39% from FY 2025) and profit margin expansion to 6.8% from 5.4%. In September 2025, Mochida agreed to acquire a 20% stake in And Pharma Co., Ltd. for ¥16.2 billion, signaling strategic expansion into emerging biotech partnerships. The company maintains a balanced dividend policy while pursuing selective M&A to strengthen its therapeutic pipeline.

Competitive Landscape

Pro stress-test →

Mochida competes in the Japanese pharmaceutical market dominated by larger integrated players (Takeda, Daiichi Sankyo, Eisai). Its strength lies in specialized therapeutic areas (gynecology, psychiatry, gastroenterology) and generic drug capabilities. The And Pharma partnership signals differentiation strategy toward regenerative medicine and niche therapeutic development rather than head-to-head competition with megacaps.

Industry Context

Mochida Pharmaceutical Co., Ltd. operates in Pharmaceuticals.

Key facts

Founded: 1913 · Headquarters: Shinjuku-ku, Tokyo, Japan · Employees: 1,479 · Revenue: ¥117.0 billion (FY 2026) · Market cap: ¥120.9-¥125.9 billion ($0.9-1.0B)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Mochida Pharmaceutical Co., Ltd..

  • FY 2026 marked inflection point: 11% revenue growth and 39% net income growth driven by operational leverage and margin expansion (6.8% vs. 5.4% prior year)
  • Strategic pivot toward partnerships: 20% stake acquisition in And Pharma (September 2025) for ¥16.2B signals M&A strategy to diversify pipeline beyond traditional generic focus
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2026Annual General Meeting held; FY 2026 results reported with strong earnings growth and margin expansion
  • May 2026Full year 2026 results announced: ¥117.0B revenue (+11%), ¥7.90B net income (+39%), profit margin 6.8%
  • +2 moreTrack every material event for Mochida Pharmaceutical Co., Ltd. as it happens. Explore monitoring →
Get alerted when Mochida Pharmaceutical Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Takeda PharmaceuticalJapan's largest pharma; diversified portfolio across oncology, gastroenterology, neurology→Daiichi SankyoMajor Japanese pharma; focus on oncology, cardiovascular, and specialty medicines→EisaiIntegrated pharma with strong R&D in neurology, oncology, and specialty care→ShionogiMid-cap Japanese pharma; specialty focus on infectious disease and oncology→

Compare Mochida Pharmaceutical Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Mochida Pharmaceutical Co., Ltd. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Mochida Pharmaceutical Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Mochida Pharmaceutical Co., Ltd. and its top competitor on Cyborg Score”
“What did Mochida Pharmaceutical Co., Ltd. do this quarter?”
“Is Mochida Pharmaceutical Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Mochida Pharmaceutical Co., Ltd. do?+
Mochida Pharmaceutical manufactures and sells pharmaceuticals and healthcare products in Japan. The company primarily develops new drugs for treating intractable diseases and generic drugs, with therapeutic focus on c...
What is Mochida Pharmaceutical Co., Ltd.'s Cyborg Score?+
Mochida Pharmaceutical Co., Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Mochida Pharmaceutical Co., Ltd.'s main competitors?+
Named competitors include Takeda Pharmaceutical, Daiichi Sankyo, Eisai, Shionogi. The full competitive landscape is in the AskCyborg report.
How can I get the full Mochida Pharmaceutical Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Mochida Pharmaceutical Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Mochida Pharmaceutical Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.6Eisai Co., Ltd.6Shionogi & Co., Ltd.